Reactive and clonal thrombocytosis

Platelets in Hematologic and Cardiovascular Disorders: A Clinical Handbook

Volumn , Issue , 2007, Pages 186-200

  Tefferi, Ayalew ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84933564577     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545276.013     Document Type: Chapter

References (155)

1. Ruocco L, Del Corso L, Romanelli AM, Deri D, Pentimone F. New hematological indices in the healthy elderly.Minerva Med 2001;92:69-73.
2. Brummitt DR, Barker HF. The determination of a reference range for new platelet parameters produced by the Bayer ADVIA120 full blood count analyser. Clin Lab Haematol 2000;22:103-7.
3. Lozano M, Narvaez J, Faundez A, et al. Platelet count and mean platelet volume in the Spanish population.Med Clin (Barc) 1998;110:774-7.
4. Gevao SM, Pabs-Garnon E, Williams AC. Platelet counts in healthy adult Sierra Leoneans.West Afr JMed 1996;15:163-4.
5. Ross DW, Ayscue LH, Watson J, Bentley SA. Stability of hematologic parameters in healthy subjects. Intraindividual versus interindividual variation. AmJ Clin Pathol 1988;90:262-7.
6. Zeng SM, Murray JC, Widness JA, Strauss RG, Yankowitz J. Association of single nucleotide polymorphisms in the thrombopoietin-receptor gene, but not the thrombopoietin gene, with differences in platelet count. AmJ Hematol 2004;77:12-21.
7. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci USA 2004;101: 11444-7.
8. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.NEngl J Med 1998;338:572-80.
9. Slee PH, van Everdingen JJ, Geraedts JP, te Velde J, den Ottolander GJ. Familial myeloproliferative disease. Hematological and cytogenetic studies. ActaMed Scand 1981;210:321-7.
10. Eyster ME, Saletan SL, Rabellino EM, et al. Familial essential thrombocythemia. AmJMed 1986;80:497-502.
11. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5_-untranslated region of the thrombopoietin gene. Blood 1998;92:1091-6.
12. Wiestner A, Schlemper RJ, Vandermaas APC, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nature Genet 1998;18:49-52.
13. Wiestner A, Padosch SA, Ghilardi N, et al. Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol 2000;110:104-9.
14. Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol 1999;107:310-16.
15. Stuhrmann M, Bashawri L, Ahmed MA, et al. Familial thrombocytosis as a recessive, possibly X-linked trait in an Arab family. Br J Haematol 2001;112:616-20.
16. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103: 4198-200.
17. Tefferi A, Gilliland DG. Classification of myeloproliferative disorders: from Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol 2006;19:361-4.
18. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J InternMed 1999;245:295-300.
19. Wiwanitkit V. Extreme thrombocytosis: what are the etiologies? Clin Appl Thromb Hemost 2006;12:85-7.
20. Aydogan T, Kanbay M, Alici O, Kosar A. Incidence and etiology of thrombocytosis in an adult Turkish population. Platelets 2006;17:328-31.
21. Matsubara K, Fukaya T, Nigami H, et al. Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta Haematol 2004;111:132-7.
22. Cortelazzo S, Viero P, Finazzi G, A. DE, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8: 556-62.
23. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.NEngl J Med 1995;332:1132-6.
24. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients.Medicine (Baltimore) 2005;84: 277-90.
25. Yamazaki-Nakashimada MA, Espinosa-Lopez M, Hernandez-Bautista V, Espinosa-Padilla S, Espinosa-Rosales F. Catastrophic Kawasaki disease or juvenile polyarteritis nodosa? Semin Arthritis Rheum 2006;35:349-54.
26. Haznedaroglu IC, Ertenli I, Ozcebe OI, et al. Megakaryocyte-related interleukins in reactive thrombocytosis versus autonomous thrombocythemia. Acta Haematol 1996;95:107-11.
27. Dan K, Gomi S, Inokuchi K, et al. Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol 1995;93:67-72.
28. Ishiguro A, Ishikita T, Shimbo T, et al. Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease. Thromb Haemost 1998;79:1096-1100.
29. Heits F, Stahl M, Ludwig D, et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res 1999;19:757-60.
30. Ertenli I, Haznedaroglu IC, Kiraz S, et al. Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatol Int 1996;16:5-8.
31. Chuncharunee S, Archararit N, Hathirat P, et al. Levels of serum interleukin-6 and tumor necrosis factor in postsplenectomized thalassemic patients. JMed Assoc Thai 1997;80(Suppl 1):S86-91.
32. Estrov Z, Talpaz M, Mavligit G, et al. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. AmJMed 1995;98: 551-8.
33. Wolber EM, JelkmannW. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res 2000;20:499-506.
34. Wolber EM, Fandrey J, Frackowski U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb Haemost 2001;86:1421-4.
35. Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997;72:424-30.
36. Takagi M, Egawa T, Motomura T, et al. Interleukin-6 secreting phaeochromocytoma associated with clinical markers of inflammation. Clin Endocrinol (Oxf) 1997;46: 507-9.
37. Hwang SJ, Luo JC, Li CP, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma.World J Gastroenterol 2004;10:2472-7.
38. Alexandrakis MG, Passam FH, Perisinakis K, et al. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. RespirMed 2002;96:553-8.
39. Dodig S, Raos M, Kovac K, et al. Thrombopoietin and interleukin-6 in children with pneumonia-associated thrombocytosis. ArchMed Res 2005;36:124-8.
40. Karakus S, Ozcebe OI, Haznedaroglu IC, et al. Circulating thrombopoietin in clonal versus reactive thrombocytosis. Hematology 2002;7:9-12.
41. Schmitt M, Gleiter CH, Nichol JL, et al. Haematological abnormalities in early abstinent alcoholics are closely associated with alterations in thrombopoietin and erythropoietin serum profiles. Thromb Haemost 1999;82:1422-7.
42. Radley JM, Hodgson GS, Thean LE, Zangheri O, Levin J. Increased megakaryocytes in the spleen during rebound thrombocytosis following 5-fluorouracil. Exp Hematol 1980;8:1129-38.
43. Haselager EM, Vreeken J. Rebound thrombocytosis after alcohol abuse: a possible factor in the pathogenesis of thromboembolic disease. Lancet 1977;1:774-5.
44. Akan H, Guven N, Aydogdu I, Arat M, Beksac M, Dalva K. Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. Acta Haematol 2000;103:152-6.
45. Geddis AE, Kaushansky K. Cross-reactivity between erythropoietin and thrombopoietin at the level of Mpl does not account for the thrombocytosis seen in iron deficiency. J Pediatr Hematol Oncol 2003;25:919-20; author reply 920.
46. Ichikawa N, Kitano K, Shimodaira S, et al. Changes in serum thrombopoietin levels after splenectomy. Acta Haematol 1998;100:137-41.
47. Croese J, Harris O, Bain B. Coeliac disease. Haematological features, and delay in diagnosis.Med J Aust 1979;2: 335-8.
48. Gertz MA, Kyle RA, Greipp PR. Hyposplenism in primary systemic amyloidosis. Ann InternMed 1983;98:475-7.
49. Chanet V, Tournilhac O, Dieu-Bellamy V, et al. Isolated spleen agenesis: a rare cause of thrombocytosis mimicking essential thrombocythemia. Haematologica 2000; 85:1211-3.
50. Halfdanarson TR, Litzow MR, Murray JA. Hematological manifestations of celiac disease. Blood 2007;109:412-21.
51. Gordon DH, Schaffner D, Bennett JM, Schwartz SI. Postsplenectomy thrombocytosis: its association with mesenteric, portal, and/or renal vein thrombosis in patients with myeloproliferative disorders. Arch Surg 1978;113:713-15.
52. Visudhiphan S, Ketsa-Ard K, Piankijagum A, Tumliang S. Blood coagulation and platelet profiles in persistent post-splenectomy thrombocytosis. The relationship to thromboembolism. Biomed Pharmacother 1985;39:264-71.
53. Dawson AA, Bennett B, Jones PF, Munro A. Thrombotic risks of staging laparotomy with splenectomy in Hodgkin's disease. Br J Surg 1981;68:842-5.
54. Boxer MA, Braun J, Ellman L. Thromboembolic risk of postsplenectomy thrombocytosis. Arch Surg 1978;113:808-9.
55. Epstein E, Goedel A. Hamorrhagische thrombozythamie bei vascularer schrumpfmilz (Hemorrhagic thrombocythemia with a vascular, sclerotic spleen). Virchows Archiv A Pathol Anat Histopathol 1934;293: 233.
56. DameshekW. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-5.
57. Gunz FW. Hemorrhagic thrombocythemia: a critical review. Blood 1960;15:706-23.
58. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol 1986;23:177-82.
59. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916-19.
60. Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press, 2001:17-44.
61. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
62. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
63. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
64. Kralovics R, Passamonti F, Buser AS, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. NEngl J Med 2005;352:1779-90.
65. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoSMed 2006;3:e270.
66. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6.
67. Scott LM, Tong W, Levine R, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.
68. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-9.
69. Ridell B, Carneskog J, Wedel H, et al. Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992. Eur J Haematol 2000;65:267-71.
70. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 1997;15:173-89.
71. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymph 1992;7:251-5.
72. Heudes D, Carli PM, Bailly F, Milan C, Mugneret F, Petrella T.Myeloproliferative disorders in the department of Cote d'Or between 1980 and 1986. Nouvelle Rev Francaise Hematol 1989;31:375-8.
73. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol 1999;61:10-15.
74. Johansson P, Kutti J, Andreasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J InternMed 2004;256: 161-5.
75. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann InternMed 2003;139:470-5.
76. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007;21:270-6.
77. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-61.
78. Randi ML, Putti MC, Fabris F, Sainati L, Zanesco L, Girolami A. Features of essential thrombocythaemia in childhood: a study of five children. Br J Haematol 2000;108: 86-9.
79. Dror Y, Zipursky A, Blanchette VS. Essential thrombocythemia in children. J Pediatr Hematol Oncol 1999;21:356-3.
80. Mele A, Visani G, Pulsoni A, et al. Risk factors for essential thrombocythemia: a case-control study. Italian Leukemia Study Group. Cancer 1996;77:2157-61.
81. Falcetta R, Sacerdote C, Bazzan M, et al. [Occupational and environmental risk factors for essential thrombocythemia: a case-control study]. G ItalMed Lav Ergon 2003; 25(Suppl 3:9-12).
82. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-termretrospective study of young women with essential thrombocythemia.Mayo Clin Proc 2001;76: 22-8.
83. Besses C, Cervantes F, Pereira A, et al.Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-4.
84. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66:549-56.
85. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann InternMed 1985;102:466-71.
86. van Genderen PJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 1996;76:333-8.
87. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991;67:2926-30.
88. Chim CS, Kwong YL, Lie AK, et al. Long-termoutcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch InternMed 2005;165:2651-8.
89. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-termcomplication rates, and prognostic factors.Mayo Clin Proc 2006;81: 159-66.
90. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
91. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann InternMed 1995;123:656-64.
92. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-termresults in 163 patients. Haematologica 2000;85: 1011-18.
93. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-32.
94. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007;109:2310-13.
95. Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol 2006;77:327-33.
96. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006;130: 2031-8.
97. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001;66:152-9.
98. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-24.
99. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-9.
100. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-termprognostic relevance. Br J Haematol 2005;131: 208-13.
101. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207-9.
102. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6.
103. Levine RL, Gilliland DG. JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol 2007;14:43-7.
104. Juvonen E, Ikkala E, Oksanen K, Ruutu T.Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993;83:192-7.
105. Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000;96: 3310-21.
106. Messinezy M, Westwood NB, El-Hemaidi I, Marsden JT, Sherwood RS, Pearson TC. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol 2002;117:47-53.
107. Yoon SY, Li CY, Tefferi A.Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur J Haematol 2000; 65:170-4.
108. Harrison CN, Gale RE, Pezella F, Mire-Sluis A, MacHin SJ, Linch DC. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Br J Haematol 1999;107:139-47.
109. Passamonti F, Pietra D, Malabarba L, et al. Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. Br J Haematol 2004;126:650-6.
110. Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 2004;103:3547-8.
111. Koch CA, Lasho TL, Tefferi A. Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. Br J Haematol 2004;127:34-9.
112. Horikawa Y, Matsumura I, Hashimoto K, et al.Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997;90:4031-8.
113. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995;74:1225-30.
114. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004;15:67-84.
115. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-32.
116. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-30.
117. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.NEngl J Med 2005;353:33-45.
118. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006;4:2593-8.
119. Tefferi A, Gangat N, Wolanskyj AP.Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 2006;108: 2493-4.
120. Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984;64:981-5.
121. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-90.
122. Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. AmJMed 1994; 97:374-8.
123. Murphy S, Davis JL, Walsh PN, Gardner FH. Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch InternMed 1978;138: 1251-3.
124. Boneu B, Nouvel C, Sie P, et al. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests. Scand J Haematol 1980;25:214-20.
125. Waddell CC, Brown JA, Repinecz YA. Abnormal platelet function in myeloproliferative disorders. Arch Pathol Lab Med 1981;105:432-5.
126. Lofvenberg E, Nilsson TK. Qualitative platelet defects in chronic myeloproliferative disorders: evidence for reduced ATP secretion. Eur J Haematol 1989;43:435-40.
127. Zahavi J, Zahavi M, Firsteter E, Frish B, Turleanu R, Rachmani R. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 1991;47: 326-32.
128. Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. AmJ Clin Pathol 1991;95:82-6.
129. Small BM, Bettigole RE. Diagnosis of myeloproliferative disease by analysis of the platelet volume distribution. Am J Clin Pathol 1981;76:685-91.
130. Sehayek E, Ben-Yosef N, Modan M, Chetrit A, Meytes D. Platelet parameters and aggregation in essential and reactive thrombocytosis. AmJ Clin Pathol 1988;90:431-6.
131. Osselaer JC, Jamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem 1997;43:1072-6.
132. Michiels JJ, Berneman Z, Schroyens W, et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 2004;83:504-12.
133. Bennett JM. The myelodysplastic/myeloproliferative disorders: the interface. Hematol Oncol Clin North Am 2003;17:1095-1100.
134. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymph 1999;33:207-18.
135. Thiele J, Kvasnicka HM. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol 2005;32:380-94.
136. Tefferi A, Elliott MA. Schistocytes on the peripheral blood smear.Mayo Clin Proc 2004;79:809.
137. Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 2005;128:42-8.
138. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 2002;108:55-65.
139. Tefferi A. Ultra high platelet count might be a characteristic feature of chronic myeloid leukemia rather than essential thrombocythemia. Leuk Res 2007;31:416-17.
140. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005;130: 153-65.
141. Vannucchi AM, Grossi A, Pancrazzi A, et al. PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. Br J Haematol 2004;127: 214-19.
142. Chiusolo P, La Barbera EO, Laurenti L, et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol 2001;29:670-6.
143. Zamora L, Espinet B, Florensa L, Besses C, Bellosillo B, Sole F. Clonality analysis by HUMARA assay in Spanish females with essential thrombocythemia and polycythemia vera. Haematologica 2005;90:259-61.
144. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33:313-20.
145. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. NEngl J Med 2004;350:114-24.
146. Storen EC, Tefferi A. Long-termuse of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6.
147. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. AmJ Hematol 1997;56: 168-72.
148. Silver RT. Interferon alfa: effects of long-termtreatment for polycythemia vera. Semin Hematol 1997;34:40-50.
149. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1, 638 patients enrolled in a prospective observational study. Blood 2005;105: 2664-70.
150. Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 1997;23:463.
151. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.NEngl J Med 1995;332:1132-6.
152. van Genderen PJ, Leenknegt H, Michiels JJ. The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link? Semin Thromb Hemost 1997; 23:385-9.
153. Grima KM. Therapeutic apheresis in hematological and oncological diseases. J Clin Apheresis 2000;15:28-52.
154. Greist A. The role of blood component removal in essential and reactive thrombocytosis. Ther Apher 2002;6:36-44.
155. Adami R. Therapeutic thrombocytapheresis: a review of 132 patients. Int J Arti Organs 1993;16(Suppl 5): 183-4.